TScan TherapeuticsTCRX
About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Employees: 199
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
25% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 5 (+1) [Q3]
11% more funds holding
Funds holding: 80 [Q2] → 89 (+9) [Q3]
0.13% more ownership
Funds ownership: 85.84% [Q2] → 85.97% (+0.13%) [Q3]
15% less capital invested
Capital invested by funds: $244M [Q2] → $209M (-$35.5M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Andrew Fein 34% 1-year accuracy 114 / 339 met price target | 533%upside $15 | Buy Reiterated | 11 Dec 2024 |
Needham Gil Blum 15% 1-year accuracy 26 / 169 met price target | 364%upside $11 | Buy Reiterated | 11 Dec 2024 |
Financial journalist opinion
Based on 3 articles about TCRX published over the past 30 days